Terms: = Bone cancer AND CD52, CDW52, EDDM5 AND Diagnosis
13 results:
1. T-Cell Prolymphocytic Leukemia With t(X;14)(q28;q11.2): A Clinicopathologic Study of 15 Cases.
Hu Z; Medeiros LJ; Xu M; Yuan J; Peker D; Shao L; Tang Z; Mai B; Thakral B; Rios A; Hu S; Wang W
Am J Clin Pathol; 2023 Apr; 159(4):325-336. PubMed ID: 36883805
[TBL] [Abstract] [Full Text] [Related]
2. Single-cell analysis reveals the chemotherapy-induced cellular reprogramming and novel therapeutic targets in relapsed/refractory acute myeloid leukemia.
Li K; Du Y; Cai Y; Liu W; Lv Y; Huang B; Zhang L; Wang Z; Liu P; Sun Q; Li N; Zhu M; Bosco B; Li L; Wu W; Wu L; Li J; Wang Q; Hong M; Qian S
Leukemia; 2023 Feb; 37(2):308-325. PubMed ID: 36543880
[TBL] [Abstract] [Full Text] [Related]
3. Subclones of bone marrow CD34
Jia R; Ji M; Li G; Xia Y; Guo S; Li P; Sun Y; Lu F; Zhang J; Zang S; Yan S; Ye J; Xue F; Ma D; Sun T; Ji C
Cancer; 2022 Nov; 128(22):3929-3942. PubMed ID: 36197314
[TBL] [Abstract] [Full Text] [Related]
4. Allogeneic hematopoietic cell transplantation in T-cell prolymphocytic leukemia: A single-center experience.
Dholaria BR; Ayala E; Sokol L; Nishihori T; Chavez JC; Hussaini M; Kumar A; Kharfan-Dabaja MA
Leuk Res; 2018 Apr; 67():1-5. PubMed ID: 29407180
[TBL] [Abstract] [Full Text] [Related]
5. TCL-1-positive hematogones in a patient with T-cell prolymphocytic leukemia after therapy.
Hu Z; Li S; Medeiros LJ; Sun T
Hum Pathol; 2017 Jul; 65():175-179. PubMed ID: 28232160
[TBL] [Abstract] [Full Text] [Related]
6. Flow cytometry-based characterization of underlying clonal B and plasma cells in patients with light chain amyloidosis.
Lisenko K; Schönland SO; Jauch A; Andrulis M; Röcken C; Ho AD; Goldschmidt H; Hegenbart U; Hundemer M
Cancer Med; 2016 Jul; 5(7):1464-72. PubMed ID: 27109862
[TBL] [Abstract] [Full Text] [Related]
7. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2014 Mar; 89(3):325-37. PubMed ID: 24577808
[TBL] [Abstract] [Full Text] [Related]
8. Alemtuzumab as a bridge to allogeneic SCT in atypical hemophagocytic lymphohistiocytosis.
Strout MP; Seropian S; Berliner N
Nat Rev Clin Oncol; 2010 Jul; 7(7):415-20. PubMed ID: 20404855
[TBL] [Abstract] [Full Text] [Related]
9. The diagnosis, management, and role of hematopoietic stem cell transplantation in aggressive peripheral T-cell neoplasms.
Rezania D; Cualing HD; Ayala E
Cancer Control; 2007 Apr; 14(2):151-9. PubMed ID: 17387300
[TBL] [Abstract] [Full Text] [Related]
10. Successful treatment of chemotherapy-refractory Sézary syndrome with alemtuzumab (Campath-1H).
Gautschi O; Blumenthal N; Streit M; Solenthaler M; Hunziker T; Zenhäusern R
Eur J Haematol; 2004 Jan; 72(1):61-3. PubMed ID: 14962265
[TBL] [Abstract] [Full Text] [Related]
11. Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: therapeutic applications and considerations.
Treon SP; Kelliher A; Keele B; Frankel S; Emmanouilides C; Kimby E; Schlossman R; Mitsiades N; Mitsiades C; Preffer F; Anderson KC
Semin Oncol; 2003 Apr; 30(2):248-52. PubMed ID: 12720146
[TBL] [Abstract] [Full Text] [Related]
12. Management of chronic lymphocytic leukaemia.
Kalil N; Cheson BD
Drugs Aging; 2000 Jan; 16(1):9-27. PubMed ID: 10733261
[TBL] [Abstract] [Full Text] [Related]
13. Chronic lymphocytic leukemia.
Keating MJ
Semin Oncol; 1999 Oct; 26(5 Suppl 14):107-14. PubMed ID: 10561025
[TBL] [Abstract] [Full Text] [Related]
